

**East of England - Cambridge East Research Ethics Committee**

The Old Chapel  
Royal Standard Place  
Nottingham  
NG1 6FS

28 September 2020

Dr Sarah E Seaton  
Research Fellow in Perinatal and Paediatric Research  
George Davies Centre  
Lancaster Road  
LE1 7RH

Dear Dr Seaton

<b>Study title:</b>	<b>Understanding the transition from neonatal to paediatric care: a data linkage study</b>
<b>REC reference:</b>	<b>20/EE/0220</b>
<b>Protocol number:</b>	<b>0793</b>
<b>IRAS project ID:</b>	<b>283808</b>

The Research Ethics Committee reviewed the above application at the meeting held on 15 September 2020. Thank you for attending to discuss the application.

**Ethical opinion**

The members of the Committee present gave a favourable ethical opinion of the above research on the basis described in the application form, protocol and supporting documentation, subject to the conditions specified below.

**Conditions of the favourable opinion**

The REC favourable opinion is subject to the following conditions being met prior to the start of the study.

Confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or NHS management permission (in Scotland) should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements. Each NHS organisation must confirm through the signing of agreements and/or other documents that it has given permission for the research to proceed (except where explicitly specified otherwise).

Guidance on applying for HRA and HCRW Approval (England and Wales)/ NHS permission for research is available in the Integrated Research Application System.

For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.

Sponsors are not required to notify the Committee of management permissions from host organisations.

### Registration of Clinical Trials

It is a condition of the REC favourable opinion that **all clinical trials are registered** on a publicly accessible database. For this purpose, 'clinical trials' are defined as the first four project categories in IRAS project filter question 2. Registration is a legal requirement for clinical trials of investigational medicinal products (CTIMPs), except for phase I trials in healthy volunteers (these must still register as a condition of the REC favourable opinion).

Registration should take place as early as possible and within six weeks of recruiting the first research participant at the latest. Failure to register is a breach of these approval conditions, unless a deferral has been agreed by or on behalf of the Research Ethics Committee ( see here for more information on requesting a deferral: <https://www.hra.nhs.uk/planning-and-improving-research/research-planning/research-registration-research-project-identifiers/>

As set out in the UK Policy Framework, research sponsors are responsible for making information about research publicly available before it starts e.g. by registering the research project on a publicly accessible register. Further guidance on registration is available at: <https://www.hra.nhs.uk/planning-and-improving-research/research-planning/transparency-responsibilities/>

You should notify the REC of the registration details. We routinely audit applications for compliance with these conditions.

### Publication of Your Research Summary

We will publish your research summary for the above study on the research summaries section of our website, together with your contact details, no earlier than three months from the date of this favourable opinion letter.

Should you wish to provide a substitute contact point, make a request to defer, or require further information, please visit: <https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/>

**N.B. If your study is related to COVID-19 we will aim to publish your research summary within 3 days rather than three months.**

During this public health emergency, it is vital that everyone can promptly identify all relevant research related to COVID-19 that is taking place globally. If you haven't already done so, please register your study on a public registry as soon as possible and provide the HRA with the registration detail, which will be posted alongside other information relating to your project. We are also asking sponsors not to request deferral of publication of research summary for any projects relating to COVID-19. In addition, to facilitate finding and extracting studies related to COVID-19 from public databases, please enter the WHO official acronym for the coronavirus disease (COVID-19) in the full title of your study. Approved COVID-19 studies can be found at: <https://www.hra.nhs.uk/covid-19-research/approved-covid-19-research/>

**It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).**

## After ethical review: Reporting requirements

The attached document “After ethical review – guidance for researchers” gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study, including early termination of the study
- Final report

The latest guidance on these topics can be found at <https://www.hra.nhs.uk/approvals-amendments/managing-your-approval/>.

## Ethical review of research sites

### NHS/HSC Sites

The favourable opinion applies to all NHS/HSC sites taking part in the study taking part in the study, subject to confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or NHS management permission (in Scotland) being obtained from the NHS/HSC R&D office prior to the start of the study (see “Conditions of the favourable opinion” below).

### Non-NHS/HSC sites

I am pleased to confirm that the favourable opinion applies to any non NHS/HSC sites listed in the application, subject to site management permission being obtained prior to the start of the study at the site.

## Approved documents

The documents reviewed and approved at the meeting were:

<i>Document</i>	<i>Version</i>	<i>Date</i>
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only)		07 August 2020
Letter from sponsor		05 August 2020
Letters of invitation to participant	1.0	05 August 2020
Letters of invitation to participant	1.0	05 August 2020
REC Application Form [REC_Form_18082020]		18 August 2020
Research protocol or project proposal	1.0	05 August 2020
Summary CV for Chief Investigator (CI)		14 August 2020

## Membership of the Committee

The members of the Ethics Committee who were present at the meeting are listed on the attached sheet.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

## User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: <http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/>

## HRA Learning

We are pleased to welcome researchers and research staff to our HRA Learning Events and online learning opportunities– see details at: <https://www.hra.nhs.uk/planning-and-improving-research/learning/>

<b>IRAS project ID: 283808</b> <b>Please quote this number on all correspondence</b>
--

With the Committee's best wishes for the success of this project.

Yours sincerely

Handwritten signature of Dr Alan Lamont, consisting of the initials 'PP' followed by a stylized signature.

**Dr Alan Lamont**  
**Chair**

E-mail: [CambridgeEast.REC@hra.nhs.uk](mailto:CambridgeEast.REC@hra.nhs.uk)

Enclosures: List of names and professions of members who were present at the meeting and those who submitted written comments.

Copy to: Cat Taylor  
*Confidentiality Advise Team*

[approvals@hra.nhs.uk](mailto:approvals@hra.nhs.uk)

## East of England - Cambridge East Research Ethics Committee

### Attendance at Committee meeting on 15 September 2020

#### Committee Members:

<i>Name</i>	<i>Profession</i>	<i>Present</i>	<i>Notes</i>
Dr Philip Bedford	Retired Study Responsible Scientist	No	
Dr Helen Burns	Retired GP	Yes	
Dr Alan Calverd	Scientific Consultant	Yes	
Mr John Chandler	Former Chief Executive PSP Association	Yes	
Mrs Ann Colvill	Retired Employment Tribunal Service	No	
Mr Edward Gibbes	Freelance journalist	Yes	
Dr Sinead Healy	Research Governance Facilitator	Yes	
Mrs Victoria Hollamby	Research Governance Advisor	Yes	
Dr Alan Lamont (Chair)	Retired Consultant Oncologist	Yes	
Mr Trevor McCann	Retired Strategic Development Consultant	Yes	
Miss Sophie Newton	Hearing Implant Research Nurse	Yes	
Dr Derek Prater	Pharmacist	Yes	
Dr Wendi Qian	Senior Statistician	Yes	
Dr Jessica Santos	Global Compliance & Quality Director	Yes	
Dr Joyce Whittington	Psychologist	No	